{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T17:34:26Z","timestamp":1770485666276,"version":"3.49.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2014,8,29]],"date-time":"2014-08-29T00:00:00Z","timestamp":1409270400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2014,8,29]],"date-time":"2014-08-29T00:00:00Z","timestamp":1409270400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                        <jats:title>Introduction<\/jats:title>\n                        <jats:p>The objective of this study was to evaluate the long-term safety and efficacy of tabalumab, a monoclonal antibody that neutralizes membrane-bound and soluble B-cell-activating factor, in rheumatoid arthritis (RA) patients.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Methods<\/jats:title>\n                        <jats:p>Patients with RA who completed one of two 24-week randomized controlled trials (RCTs) participated in this 52-week, flexible-dose, open-label extension study. Patients in RCT1 received intravenous placebo, 30-mg tabalumab or 80-mg tabalumab every 3 weeks, and patients in RCT2 received subcutaneous placebo or 1-, 3-, 10-, 30-, 60- or 120-mg tabalumab every 4 weeks (Q4W). Regardless of prior treatment, all patients in this study received subcutaneous 60-mg tabalumab Q4W for the first 3 months, then a one-time increase to 120-mg tabalumab Q4W (60-mg\/120-mg group) and a one-time decrease to 60-mg tabalumab Q4W per patient was allowed (60-mg\/120-mg\/60-mg group).<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Results<\/jats:title>\n                        <jats:p>There were 182 patients enrolled: 60 mg (<jats:italic>n<\/jats:italic> = 60), 60\/120 mg (<jats:italic>n<\/jats:italic> = 121) and 60\/120\/60 mg (<jats:italic>n<\/jats:italic> = 1). Pretabalumab baseline disease activity was generally higher in the 60-mg\/120-mg group. There was a higher frequency of serious adverse events and treatment-emergent adverse events, as well as infections and injection-site reactions, in the 60-mg\/120-mg group. One death unrelated to the study drug occurred (60-mg\/120-mg group). In both groups, total B-cell counts decreased by approximately 40% from the baseline level in the RCT originating study. Both groups demonstrated efficacy through 52 weeks of treatment relative to baseline pretabalumab disease activity based on American College of Rheumatology criteria improvement \u226520%, \u226550% and \u226570%; European League against Rheumatism Responder Index in 28 joints; Disease Activity Score in 28 joints-C-reactive protein; and Health Assessment Questionnaire-Disability Index.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Conclusions<\/jats:title>\n                        <jats:p>With long-term, open-label tabalumab treatment, no unexpected safety signals were observed, and B-cell reductions were consistent with previous findings. Despite differences in RCT originating studies, both groups demonstrated an efficacy response through the 52-week extension.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Trial registration<\/jats:title>\n                        <jats:p>ClinicalTrials.gov Identifier: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00837811?term=NCT00837811&amp;rank=1\">NCT00837811<\/jats:ext-link> (registered 3 February 2009).<\/jats:p>\n                     <\/jats:sec>","DOI":"10.1186\/s13075-014-0415-2","type":"journal-article","created":{"date-parts":[[2014,8,28]],"date-time":"2014-08-28T09:57:33Z","timestamp":1409219853000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["A 52-week, open-label study evaluating the safety and efficacy of tabalumab, an anti-B-cell-activating factor monoclonal antibody, for rheumatoid arthritis"],"prefix":"10.1186","volume":"16","author":[{"given":"Maria","family":"Greenwald","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leszek","family":"Szczepanski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alastair","family":"Kennedy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa","family":"Veenhuizen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wendy J","family":"Komocsar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emery","family":"Polasek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelly","family":"Guerrettaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre-Yves","family":"Berclaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,8,29]]},"reference":[{"key":"415_CR1","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1084\/jem.189.11.1747","volume":"189","author":"P Schneider","year":"1999","unstructured":"Schneider P, MacKay F, Steiner V, Hofmann K, Bodmer JL, Holler N, Ambrose C, Lawton P, Bixler S, Acha-Orbea H, Valmori D, Romero P, Werner-Favre C, Zubler RH, Browning JL, Tschopp J: BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med. 1999, 189: 1747-1756. 10.1084\/jem.189.11.1747.","journal-title":"J Exp Med"},{"key":"415_CR2","first-page":"1256","volume":"35","author":"S Bosello","year":"2008","unstructured":"Bosello S, Youinou P, Daridon C, Tolusso B, Bendaoud B, Pietrapertosa D, Morelli A, Ferraccioli G: Concentrations of BAFF correlate with autoantibody levels, clinical disease activity, and response to treatment in early rheumatoid arthritis. J Rheumatol. 2008, 35: 1256-1264.","journal-title":"J Rheumatol"},{"key":"415_CR3","first-page":"693","volume":"60","author":"K Kikly","year":"2009","unstructured":"Kikly K, Manetta J, Smith H, Wierda D, Witcher D: Characterization of LY2127399, a neutralizing antibody for BAFF [abstract]. Arthritis Rheum. 2009, 60: 693-","journal-title":"Arthritis Rheum"},{"key":"415_CR4","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1136\/annrheumdis-2012-202775","volume":"72","author":"MC Genovese","year":"2013","unstructured":"Genovese MC, Fleischmann RM, Greenwald M, Satterwhite J, Veenhuizen M, Xie L, Berclaz PY, Myers S, Benichou O: Tabalumab, an anti-BAFF monoclonal antibody, in patients with active rheumatoid arthritis with an inadequate response to TNF inhibitors. Ann Rheum Dis. 2013, 72: 1461-1468. 10.1136\/annrheumdis-2012-202775.","journal-title":"Ann Rheum Dis"},{"key":"415_CR5","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1136\/annrheumdis-2012-202864","volume":"72","author":"MC Genovese","year":"2013","unstructured":"Genovese MC, Lee E, Satterwhite J, Veenhuizen M, Disch D, Berclaz PY, Myers S, Sides G, Benichou O: A phase 2 dose-ranging study of subcutaneous tabalumab for the treatment of patients with active rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis. 2013, 72: 1453-1460. 10.1136\/annrheumdis-2012-202864.","journal-title":"Ann Rheum Dis"},{"key":"415_CR6","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1002\/art.37820","volume":"65","author":"MC Genovese","year":"2013","unstructured":"Genovese MC, Bojin S, Biagini IM, Mociran E, Cristei D, Mirea G, Georgescu L, Sloan-Lancaster J: Tabalumab in rheumatoid arthritis patients with an inadequate response to methotrexate and naive to biologic therapy: a phase II, randomized, placebo-controlled trial. Arthritis Rheum. 2013, 65: 880-889. 10.1002\/art.37820.","journal-title":"Arthritis Rheum"},{"key":"415_CR7","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/art.1780310302","volume":"31","author":"FC Arnett","year":"1988","unstructured":"Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, Medsger TA, Mitchell DM, Neustadt DH, Pinals RS, Schaller JG, Sharp JT, Wilder RL, Hunder GG: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988, 31: 315-324. 10.1002\/art.1780310302.","journal-title":"Arthritis Rheum"},{"key":"415_CR8","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1517\/14712590903033919","volume":"9","author":"C Bracewell","year":"2009","unstructured":"Bracewell C, Isaacs JD, Emery P, Ng WF: Atacicept, a novel B cell-targeting biological therapy for the treatment of rheumatoid arthritis. Expert Opin Biol Ther. 2009, 9: 909-919. 10.1517\/14712590903033919.","journal-title":"Expert Opin Biol Ther"},{"key":"415_CR9","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1517\/14712598.2012.758248","volume":"13","author":"X Jin","year":"2013","unstructured":"Jin X, Ding C: Belimumab-an anti-BLyS human monoclonal antibody for rheumatoid arthritis. Expert Opin Biol Ther. 2013, 13: 315-322. 10.1517\/14712598.2012.758248.","journal-title":"Expert Opin Biol Ther"},{"key":"415_CR10","doi-asserted-by":"publisher","first-page":"558","DOI":"10.3899\/jrheum.090856","volume":"37","author":"RF van Vollenhoven","year":"2010","unstructured":"van Vollenhoven RF, Emery P, Bingham CO, Keystone EC, Fleischmann R, Furst DE, Macey K, Sweetser M, Kelman A, Rao R: Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials. J Rheumatol. 2010, 37: 558-567. 10.3899\/jrheum.090856.","journal-title":"J Rheumatol"},{"key":"415_CR11","doi-asserted-by":"publisher","first-page":"R141","DOI":"10.1186\/ar3455","volume":"13","author":"MH Schiff","year":"2011","unstructured":"Schiff MH, Kremer JM, Jahreis A, Vernon E, Isaacs JD, van Vollenhoven RF: Integrated safety in tocilizumab clinical trials. Arthritis Res Ther. 2011, 13: R141-10.1186\/ar3455.","journal-title":"Arthritis Res Ther"},{"key":"415_CR12","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1002\/acr.21876","volume":"65","author":"P Nash","year":"2013","unstructured":"Nash P, Nayiager S, Genovese MC, Kivitz AJ, Oelke K, Ludivico C, Palmer W, Rodriguez C, Delaet I, Elegbe A, Corbo M: Immunogenicity, safety, and efficacy of abatacept administered subcutaneously with or without background methotrexate in patients with rheumatoid arthritis: results from a phase III, international, multicenter, parallel-arm, open-label study. Arthritis Care Res. 2013, 65: 718-728. 10.1002\/acr.21876.","journal-title":"Arthritis Care Res"},{"key":"415_CR13","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.1001\/jama.2011.1692","volume":"306","author":"CG Grijalva","year":"2011","unstructured":"Grijalva CG, Chen L, Delzell E, Baddley JW, Beukelman T, Winthrop KL, Griffin MR, Herrinton LJ, Liu L, Ouellet-Hellstrom R, Patkar NM, Solomon DH, Lewis JD, Xie F, Saag KG, Curtis JR: Initiation of tumor necrosis factor-\u03b1 antagonists and the risk of hospitalization for infection in patients with autoimmune diseases. JAMA. 2011, 306: 2331-2339. 10.1001\/jama.2011.1692.","journal-title":"JAMA"},{"key":"415_CR14","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/j.autrev.2013.06.011","volume":"12","author":"F Atzeni","year":"2013","unstructured":"Atzeni F, Sarzi-Puttini P, Mutti A, Bugatti S, Cavagna L, Caporali R: Long-term safety of abatacept in patients with rheumatoid arthritis. Autoimmun Rev. 2013, 12: 1115-1117. 10.1016\/j.autrev.2013.06.011.","journal-title":"Autoimmun Rev"},{"key":"415_CR15","unstructured":"Eli Lilly & Co: Lilly discontinues one of three phase 3 rheumatoid arthritis registration studies for tabalumab: FLEX-M study did not meet efficacy expectations in an interim futility analysis; discontinuation not based on safety concerns. (press release issued 13 December 2012). (accessed 5 September 2014)., [https:\/\/investor.lilly.com\/releasedetail.cfm?releaseid=726712]"},{"key":"415_CR16","unstructured":"Eli Lilly & Co: Lilly discontinues phase 3 rheumatoid arthritis program for tabalumab based on efficacy results: decision not based on safety concerns; phase 3 lupus program continues as planned (press release issued 7 February 2013). (accessed 5 September 2014)., [https:\/\/investor.lilly.com\/releasedetail.cfm?releaseid=738769]"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-014-0415-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-014-0415-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-014-0415-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-014-0415-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T16:18:45Z","timestamp":1728922725000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-014-0415-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8,29]]},"references-count":16,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2014,8]]}},"alternative-id":["415"],"URL":"https:\/\/doi.org\/10.1186\/s13075-014-0415-2","relation":{},"ISSN":["1478-6354"],"issn-type":[{"value":"1478-6354","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,8,29]]},"assertion":[{"value":"4 February 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2014","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2014","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"415"}}